New Velcade®-melphalan Transplant Regimen for Multiple Myeloma(11/20/2009) Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.
Pomalidomide Active for Treatment of Anemia of Myelofibrosis(8/21/2009) Researchers involved in an international trial have reported that pomalidomide is active for the treatment of anemia associated with myelofibrosis. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on August 3, 2009.
Pesticides Linked to Monoclonal Gammopathy of Undetermined Significance (MGUS)(7/1/2009) Researchers from the National Cancer Institute have reported that individuals who apply pesticides to crops are twice as likely as the general population to develop monoclonal gammopathy of undetermined significance (MGUS), which can lead to multiple myeloma. The details of this study appeared in the June 18, 2009 issue of Blood.
Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers(6/25/2009) Researchers from the National Cancer Institute have reported that industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphohematopoietic malignancies, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma, according to the results of a study published in the Journal of the National Cancer Institute.
Mozobil™ Increases Autologous Peripheral Blood Stem Cell Harvests in Myeloma Patients(5/7/2009) Researchers from several U.S. medical centers have reported that the addition of Mozobil® (plerixafor, AMD3100) to Neupogen® (filgrastim) significantly increases the efficiency of autologous peripheral blood stem cell harvests in patients with multiple myeloma. The details of this study appeared in an early online publication in Blood on April 10, 2009.
In-vitro Studies Suggest that Green Tea May Interfere with Velcade®(3/17/2009) Researchers from the University of Southern California have reported that consumption of green tea may be contraindicated for patients who are receiving treatment with Velcade® (bortezomib), as the polyphenols in green tea may negate the therapeutic benefits of the drug. The details of this in-vitro study were announced in an early online publication in Blood on February 3, 2009.
New Agents for the Treatment of Multiple Myeloma Presented at ASH 2008(1/23/2009) At the 2008 meeting of the American Society of Hematology in San Francisco in December, there were several oral presentations of new and promising agents for the treatment of patients with multiple myeloma.
Revlimid® Combinations for Newly Diagnosed Multiple Myeloma Reported at ASH 2008(1/23/2009) At the 2008 meeting of the American Society of Hematology in December there were several oral presentations on the outcomes of newly diagnosed patients with multiple myeloma where Revlimid® (lenalidomide) was incorporated into the induction or maintenance regimens.
New Proteasome Inhibitor, Carfilzomab, Has Significant Activity in Relapsed Myeloma(10/6/2009) Researchers affiliated with the Multiple Myeloma Research Consortium (MMRC) have reported that carfilzomab monotherapy is highly active in patients with relapsed myeloma and can be administered safely for at least one year in responding patients. The details of this study were presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Revlimid®-based Regimen with Neulasta® Support Very Effective for Relapsed Myeloma(3/18/2009) Researchers affiliated with the German Myeloma Study Group have reported that a regimen of Revlimid® (lenalidomide), Adriamycin® (doxorubicin), and dexamethasone supported by Neulasta® (pegfilgrastim) resulted in a 74% complete or very good partial remission rate in patients with relapsed and refractory multiple myeloma. The details of this study appeared in an early online publication in Blood of January 30, 2009.
Revlimid®, Melphalan, Prednisone, and Thalomid® Effective for Relapsed Myeloma(3/3/2009) Researchers from Italy have reported that the combination of Revlimid® (lenalidomide), melphalan, prednisone, and Thalomid® (thalidomide) results in a 76% response rate in patients with relapsed or refractory multiple myeloma. The details of this study were presented on December 9 at the 2008 meeting of the American Society of Hematology.
New Agents for the Treatment of Multiple Myeloma Presented at ASH 2008(1/23/2009) At the 2008 meeting of the American Society of Hematology in San Francisco in December, there were several oral presentations of new and promising agents for the treatment of patients with multiple myeloma.
Velcade® and Perifosine Effective in Relapsed Multiple Myeloma Previously Treated with Velcade(1/22/2009) Researchers from several U.S. institutions have reported a 40% overall response rate to the combination of perifosine and Velcade® (bortizomib) in patients with multiple myeloma who had been previously treated with Velcade. The details of this study were presented at the 2008 meeting of the American Society of Hematology on December 9 in San Francisco.
Patient Home
